Despite significantly lower sales for HPV testing in the U.S., Qiagen's instrument and consumable sales propped up third quarter results.
Todd Campbell, The Motley Fool, The Motley Fool
Fri, 10/31/2014 - 6:26am
Despite significantly lower sales for HPV testing in the U.S., Qiagen's instrument and consumable sales propped up third quarter results.